Provided by Tiger Trade Technology Pte. Ltd.

Arrowhead Pharmaceuticals

60.73
-2.0200-3.22%
Post-market: 60.750.0200+0.03%19:30 EDT
Volume:1.20M
Turnover:72.89M
Market Cap:8.55B
PE:-26.59
High:62.50
Open:62.49
Low:60.48
Close:62.75
52wk High:95.49
52wk Low:34.61
Shares:140.86M
Float Shares:122.00M
Volume Ratio:0.58
T/O Rate:0.98%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-2.2838
EPS(LYR):-0.0122
ROE:-55.21%
ROA:-8.10%
PB:18.38
PE(LYR):-4,980.73

Loading ...

Arrowhead announces interim topline data from Phase 1/2a trial of ARO-DIMER-PA

TIPRANKS
·
Sep 15

Arrowhead Pharmaceuticals - Single Dose Escalation Completed Through 400 Mg; no Drug-Related Saes Reported

THOMSON REUTERS
·
Sep 15

Arrowhead Pharmaceuticals Announces Interim Topline Clinical Data for the First Dual-Functional Rnai Therapeutic for the Treatment of Mixed Hyperlipidemia

THOMSON REUTERS
·
Sep 15

Arrowhead Pharmaceuticals - Mean Maximal Non-Hdl Cholesterol Reduction of 61% with Single Dose

THOMSON REUTERS
·
Sep 15

Citi adds ‘upside 30-day catalyst watch’ on Arrowhead

TIPRANKS
·
Sep 09

Citigroup Initiates Arrowhead Pharmaceuticals at Buy With $108 Price Target

MT Newswires Live
·
Sep 08

Arrowhead Pharmaceuticals : Citigroup Initiates Coverage with Buy Rating; Target Price $108

THOMSON REUTERS
·
Sep 08

U.S. Research Roundup-Fedex Freight Holding Company, PDF Solutions, Robinhood Markets

Reuters
·
Sep 08

This Biotech Wins a Big FDA Approval. Why Wall Street is Shrugging.

Dow Jones
·
Sep 05

Arrowhead Pharma to Present at Cantor Global Healthcare Conference

Reuters
·
Sep 03

Arrowhead Pharmaceuticals' sHTG Therapy Could Get FDA Approval by Q2 2027, RBC Says

MT Newswires Live
·
Aug 31

Arrowhead Pharmaceuticals Price Target Maintained with a $100.00/Share by RBC Capital

Dow Jones
·
Aug 31

Arrowhead Pharmaceuticals Posts ESC 2026 Investor Presentation on Shasta-3 and Shasta-4 Results

Reuters
·
Aug 31

Sector Update: Healthcare

MT Newswires Live
·
Aug 31

Arrowhead Pharmaceuticals' Plozasiran Meets Endpoints in Studies of Patients With Severe Hypertriglyceridemia

MT Newswires Live
·
Aug 31

Arrowhead Phase 3 SHASTA-3, SHASTA-4 studies met primary endpoints

TIPRANKS
·
Aug 31

Arrowhead Pharmaceuticals - Plozasiran Demonstrated Favorable Safety and Tolerability Profile in Phase 3 Studies

THOMSON REUTERS
·
Aug 30

Arrowhead Pharmaceuticals - to File Supplemental Nda with U.S. FDA by Year-End 2026 Using Priority Review Voucher

THOMSON REUTERS
·
Aug 30

Arrowhead Pharmaceuticals Presents Phase 3 Shasta-3 and Shasta-4 Data Demonstrating Plozasiran Reduced Acute Pancreatitis Events in Patients with Severe Hypertriglyceridemia

THOMSON REUTERS
·
Aug 30

Arrowhead Pharma Director Michael S. Perry Disposes of 11,600 Shares for $1.01 Million

Reuters
·
Aug 21